| Year |
Citation |
Score |
| 2023 |
Fagin JA, Nikiforov YE. Progress in Thyroid Cancer Genomics: A 40-Year Journey. Thyroid : Official Journal of the American Thyroid Association. PMID 37668657 DOI: 10.1089/thy.2023.0045 |
0.317 |
|
| 2023 |
Landa I, Thornton CE, Xu B, Haase J, Krishnamoorthy GP, Hao J, Knauf JA, Herbert ZT, Martínez P, Blasco MA, Ghossein R, Fagin JA. Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects. Molecular Cancer Research : McR. PMID 37478162 DOI: 10.1158/1541-7786.MCR-23-0144 |
0.353 |
|
| 2023 |
Fagin JA, Krishnamoorthy GP, Landa I. Pathogenesis of cancers derived from thyroid follicular cells. Nature Reviews. Cancer. PMID 37438605 DOI: 10.1038/s41568-023-00598-y |
0.319 |
|
| 2023 |
Landa I, Thornton CE, Xu B, Haase J, Krishnamoorthy GP, Hao J, Knauf JA, Herbert ZT, Blasco MA, Ghossein R, Fagin JA. Telomerase reactivation induces progression of mouse Braf -driven thyroid cancers without telomere lengthening. Biorxiv : the Preprint Server For Biology. PMID 36747657 DOI: 10.1101/2023.01.24.525280 |
0.366 |
|
| 2022 |
Spourquet C, Delcorte O, Lemoine P, Dauguet N, Loriot A, Achouri Y, Hollmén M, Jalkanen S, Huaux F, Lucas S, Meerkeeck PV, Knauf JA, Fagin JA, Dessy C, Mourad M, et al. BRAF Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages. Cancers. 14. PMID 36230610 DOI: 10.3390/cancers14194687 |
0.315 |
|
| 2022 |
Boucai L, Salas-Lucia F, Krishnamoorthy GP, Sherman E, Rudin CM, Drilon A, Bianco AC, Fagin JA. Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. Jco Precision Oncology. 6: e2100496. PMID 35704797 DOI: 10.1200/PO.21.00496 |
0.331 |
|
| 2022 |
Tchekmedyian V, Dunn L, Sherman EJ, Baxi SS, Grewal R, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra M, Fish S, Boucai L, Walters J, Ghossein R, Seshan V, ... ... Fagin JA, et al. Enhancing Radioiodine Incorporation in BRAF-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial. Thyroid : Official Journal of the American Thyroid Association. PMID 35045748 DOI: 10.1089/thy.2021.0565 |
0.306 |
|
| 2021 |
Boucai L, Seshan V, Williams M, Knauf JA, Saqcena M, Ghossein RA, Fagin JA. Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score. The Journal of Clinical Endocrinology and Metabolism. PMID 34897468 DOI: 10.1210/clinem/dgab851 |
0.317 |
|
| 2021 |
Lee M, Untch BR, Xu B, Ghoissein R, Han C, Kuo F, Valero C, Nadeem Z, Patel N, Makarov V, Dogan S, Wong RJ, Sherman EJ, Ho AL, Chan TA, ... Fagin JA, et al. Genomic and transcriptomic correlates of thyroid carcinoma evolution after BRAF inhibitor therapy. Molecular Cancer Research : McR. PMID 34635506 DOI: 10.1158/1541-7786.MCR-21-0442 |
0.345 |
|
| 2021 |
Luckett KA, Cracchiolo JR, Krishnamoorthy GP, Leandro-Garcia LJ, Nagarajah J, Saqcena M, Lester R, Im SY, Zhao Z, Lowe SW, de Stanchina E, Sherman EJ, Ho AL, Leach SD, Knauf JA, ... Fagin JA, et al. Co-inhibition of SMAD and MAPK signaling enhances 124I update in BRAF-mutant thyroid cancers. Endocrine-Related Cancer. PMID 33890869 DOI: 10.1530/ERC-21-0017 |
0.375 |
|
| 2020 |
Saqcena M, Leandro-Garcia LJ, Maag JLV, Tchekmedyian V, Krishnamoorthy GP, Tamarapu PP, Tiedje V, Reuter V, Knauf JA, de Stanchina E, Xu B, Liao XH, Refetoff S, Ghossein R, Chi P, ... ... Fagin JA, et al. SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies. Cancer Discovery. PMID 33318036 DOI: 10.1158/2159-8290.CD-20-0735 |
0.338 |
|
| 2020 |
Xu B, Fuchs TL, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman EJ, Gill AJ, Ghossein R. Dissecting Anaplastic Thyroid Carcinoma (ATC): A Comprehensive Clinical, histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid : Official Journal of the American Thyroid Association. PMID 32284020 DOI: 10.1089/Thy.2020.0086 |
0.361 |
|
| 2020 |
Burman B, Sherman EJ, Kriplani A, Michel LS, Dunn L, Fetten JV, Warner E, Grewal RK, Sabra M, Tuttle RM, Boucai L, Fish S, Haque S, Ostrovnaya I, Ghossein RA, ... ... Fagin JA, et al. Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers. Journal of Clinical Oncology. 38: 6587-6587. DOI: 10.1200/Jco.2020.38.15_Suppl.6587 |
0.394 |
|
| 2019 |
Tiedje V, Fagin JA. Therapeutic breakthroughs for metastatic thyroid cancer. Nature Reviews. Endocrinology. PMID 31819229 DOI: 10.1038/S41574-019-0307-2 |
0.421 |
|
| 2019 |
Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 6883-6884. PMID 31732665 DOI: 10.1158/1078-0432.Ccr-19-2531 |
0.394 |
|
| 2019 |
Fletcher A, Read ML, Thornton CEM, Larner DP, Poole VL, Brookes K, Nieto HR, Alshahrani M, Thompson RJ, Lavery GG, Landa I, Fagin JA, Campbell MJ, Boelaert K, Turnell AS, et al. Targeting novel sodium iodide symporter interactors ADP-ribosylation factor 4 (ARF4) and valosin-containing protein (VCP) enhances radioiodine uptake. Cancer Research. PMID 31672844 DOI: 10.1158/0008-5472.Can-19-1957 |
0.352 |
|
| 2019 |
Landa-Lopez I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, et al. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30737244 DOI: 10.1158/1078-0432.Ccr-18-2953 |
0.404 |
|
| 2019 |
Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera D, Landa-Lopez I, Knauf JA, Fagin JA, et al. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Molecular Cancer Research : McR. PMID 30733375 DOI: 10.1158/1541-7786.Mcr-18-1026 |
0.437 |
|
| 2019 |
Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, Dogan S, Aleynick N, Seshan V, Middha S, Enepekides D, Casadei GP, Solaroli E, Tallini G, Ghossein R, et al. Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. Endocrine. PMID 30689169 DOI: 10.1007/S12020-019-01848-6 |
0.366 |
|
| 2018 |
Boufraqech M, Patel D, Nilubol N, Powers AS, King T, Shell J, Lack J, Zhang L, Gara SK, Gunda V, Klubo-Gwiezdzinska J, Kumar S, Fagin JA, Knauf J, Parangi S, et al. Lysyl Oxidase is a key player in BRAF/MAPK pathway-driven thyroid cancer aggressiveness. Thyroid : Official Journal of the American Thyroid Association. PMID 30398411 DOI: 10.1089/Thy.2018.0424 |
0.448 |
|
| 2018 |
Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein R, ... ... Fagin JA, et al. EIF1AX and RAS mutations cooperate to drive thyroid tumorigenesis through ATF4 and c-MYC. Cancer Discovery. PMID 30305285 DOI: 10.1158/2159-8290.Cd-18-0606 |
0.415 |
|
| 2018 |
Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, Larson SM, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, ... ... Fagin JA, et al. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. The Journal of Clinical Endocrinology and Metabolism. PMID 30256977 DOI: 10.1210/Jc.2018-01478 |
0.394 |
|
| 2018 |
Boucai L, Falcone J, Ukena J, Coombs CC, Zehir A, Ptashkin R, Berger MF, Levine RL, Fagin JA. Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival. The Journal of Clinical Endocrinology and Metabolism. PMID 30137527 DOI: 10.1210/Jc.2018-00803 |
0.4 |
|
| 2018 |
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, ... ... Fagin JA, et al. Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell. 34: 256-270.e5. PMID 30107176 DOI: 10.1016/J.Ccell.2018.07.002 |
0.332 |
|
| 2018 |
Beckham TH, Romesser PB, Groen AH, Sabol C, Shaha AR, Sabra M, Brinkman T, Spielsinger DJ, McBride S, Tsai J, Riaz N, Tuttle RM, Fagin JA, Sherman EJ, Wong RJ, et al. Intensity Modulated Radiation Therapy with or without Concurrent Chemotherapy in Non-Anaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. Thyroid : Official Journal of the American Thyroid Association. PMID 30105947 DOI: 10.1089/Thy.2018.0214 |
0.327 |
|
| 2018 |
Knauf JA, Luckett KA, Chen KY, Voza F, Socci ND, Ghossein R, Fagin JA. Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers. The Journal of Clinical Investigation. PMID 29990309 DOI: 10.1172/Jci120966 |
0.452 |
|
| 2018 |
Ferris RL, Nikiforov Y, Terris D, Seethala RR, Ridge JA, Angelos P, Duh QY, Wong R, Sabra MM, Fagin JA, McIver B, Bernet VJ, Harrell RM, Busaidy N, Cibas ES, et al. AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State-of-the-art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Head & Neck. PMID 29947030 DOI: 10.1002/Hed.25141 |
0.341 |
|
| 2018 |
Marlow LA, Rohl SD, Miller JL, Knauf JA, Fagin JA, Ryder M, Milosevic D, Netzel BC, Grebe SK, Reddi HV, Smallridge RC, Copland JA. Methodology, criteria and characterization of patient-matched thyroid cell lines and patient-derived tumor xenografts. The Journal of Clinical Endocrinology and Metabolism. PMID 29846633 DOI: 10.1210/Jc.2017-01845 |
0.414 |
|
| 2018 |
Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA. Tipifarnib inhibits HRAS-driven dedifferentiated thyroid cancers. Cancer Research. PMID 29760048 DOI: 10.1158/0008-5472.Can-17-1925 |
0.407 |
|
| 2018 |
Sherman EJ, Ho AL, Fagin JA, Haque S, Robinson C, Ghossein RA, Chen HX, Pfister DG. Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAF-mutant thyroid cancer. Journal of Clinical Oncology. 36: 6087-6087. DOI: 10.1200/Jco.2018.36.15_Suppl.6087 |
0.432 |
|
| 2017 |
Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, et al. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. Jama Otolaryngology-- Head & Neck Surgery. PMID 28859191 DOI: 10.1001/Jamaoto.2017.1442 |
0.397 |
|
| 2017 |
Sherman EJ, Dunn LA, Ho AL, Baxi SS, Ghossein RA, Fury MG, Haque S, Sima CS, Cullen G, Fagin JA, Pfister DG. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer. PMID 28662274 DOI: 10.1002/Cncr.30861 |
0.39 |
|
| 2017 |
Bellelli R, Vitagliano D, Federico G, Marotta P, Tamburrino A, Salerno P, Paciello O, Papparella S, Knauf JA, Fagin JA, Refetoff S, Troncone G, Santoro M. Oncogene-induced senescence and its evasion in a mouse model of thyroid neoplasia. Molecular and Cellular Endocrinology. PMID 28652169 DOI: 10.1016/J.Mce.2017.06.023 |
0.418 |
|
| 2017 |
Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje Vasudeva S, Carlson D, Migliacci J, Knauf JA, Untch BR, Berger MF, Morris LG, Tuttle RM, Chan TA, ... Fagin JA, et al. Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28634282 DOI: 10.1158/1078-0432.Ccr-17-1183 |
0.438 |
|
| 2017 |
Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA. Transposon mutagenesis identifies chromatin modifiers cooperating with Ras in thyroid tumorigenesis and detects ATXN7 as a cancer gene. Proceedings of the National Academy of Sciences of the United States of America. PMID 28584132 DOI: 10.1073/Pnas.1702723114 |
0.456 |
|
| 2017 |
Untch BR, Anjos VD, Garcia-Rendueles ME, Knauf JA, Ho AL, Fagin JA. Abstract 2063: The farnesyltransferase inhibitor tipifarnib causes dramatic tumor regression and increases survival in murine HrasG12Vdriven aggressive thyroid cancers: Consequent adaptive and acquired resistance mechanisms inform combination treatments with improved responses Cancer Research. 77: 2063-2063. DOI: 10.1158/1538-7445.Am2017-2063 |
0.403 |
|
| 2017 |
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. Abstract 1225: A unified model of RAF inhibitor action determines inhibitor activity in BRAF-dependent tumors Cancer Research. 77: 1225-1225. DOI: 10.1158/1538-7445.Am2017-1225 |
0.367 |
|
| 2016 |
Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, Larson S, Fagin JA, Schlumberger M, Tuttle MR. Comparison Of Empiric Versus Whole Body/Blood Clearance Dosimetry-Based Approach To Radioactive Iodine Treatment In Patients With Metastases From Differentiated Thyroid Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27738010 DOI: 10.2967/Jnumed.116.179606 |
0.369 |
|
| 2016 |
Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, ... ... Fagin JA, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. The Journal of Clinical Investigation. PMID 27669459 DOI: 10.1172/Jci89067 |
0.459 |
|
| 2016 |
Fagin JA, Wells SA. Biologic and Clinical Perspectives on Thyroid Cancer. The New England Journal of Medicine. 375: 1054-67. PMID 27626519 DOI: 10.1056/Nejmra1501993 |
0.377 |
|
| 2016 |
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C, Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI. An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. PMID 27523909 DOI: 10.1016/J.Ccell.2016.06.024 |
0.317 |
|
| 2016 |
Azouzi N, Cailloux J, Cazarin JM, Knauf JA, Cracchiolo J, Al Ghuzlan A, Hartl D, Polak M, Carre A, El Mzibri M, Filali-Maltouf A, Al Bouzidi A, Schlumberger M, Fagin JA, Ameziane-El-Hassani R, et al. NADPH oxidase NOX4 is a critical mediator of BRAFV600E-induced down regulation of the sodium iodide symporter in papillary thyroid carcinomas. Antioxidants & Redox Signaling. PMID 27401113 DOI: 10.1089/Ars.2015.6616 |
0.402 |
|
| 2016 |
Dogan S, Wang L, Ptashkin RN, Dawson RR, Shah JP, Sherman EJ, Michael Tuttle R, Fagin JA, Klimstra DS, Katabi N, Ghossein RA. Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27282352 DOI: 10.1038/Modpathol.2016.115 |
0.434 |
|
| 2016 |
Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, ... ... Fagin JA, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. The Journal of Clinical Investigation. PMID 26878173 DOI: 10.1172/Jci85271 |
0.419 |
|
| 2016 |
Dunn L, Sherman EJ, Baxi SS, Grewal RK, Pentlow KS, Haque S, Tuttle RM, Sabra M, Fish S, Boucai L, Ni A, Knauf J, Pfister DG, Fagin JA, Ho AL. Enhancing radioiodine (RAI) incorporation into BRAFV600E-mutant, RAI-refractory thyroid cancers with the BRAF inhibitor vemurafenib: A pilot study. Journal of Clinical Oncology. 34: 6099-6099. DOI: 10.1200/Jco.2016.34.15_Suppl.6099 |
0.401 |
|
| 2016 |
Krishnamoorthy GP, Landa I, Knauf JA, Nagarajah J, Rätsch G, Wendel H, Fagin JA. Abstract 892: Functional characterization of EIF1AX mutations in thyroid cancer predicts for gain of function by increasing translational rate with concomitant derepression of upstream inputs from mTOR Cancer Research. 76: 892-892. DOI: 10.1158/1538-7445.Am2016-892 |
0.419 |
|
| 2015 |
Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH, Landa I, Button J, Lailler N, Sboner A, Gao D, ... ... Fagin JA, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. PMID 26444240 DOI: 10.1038/Nature15258 |
0.369 |
|
| 2015 |
Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, ... ... Fagin JA, et al. NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition. Cancer Discovery. PMID 26359368 DOI: 10.1158/2159-8290.Cd-15-0330 |
0.382 |
|
| 2015 |
Dunn L, Fagin JA. Therapy: Lenvatinib and radioiodine-refractory thyroid cancers. Nature Reviews. Endocrinology. 11: 325-7. PMID 25824678 DOI: 10.1038/Nrendo.2015.53 |
0.35 |
|
| 2015 |
Wang LY, Smith AW, Palmer FL, Tuttle RM, Mahrous A, Nixon IJ, Patel SG, Ganly I, Fagin JA, Boucai L. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid : Official Journal of the American Thyroid Association. 25: 300-7. PMID 25386760 DOI: 10.1089/thy.2014.0287 |
0.301 |
|
| 2015 |
Xing M, Alzahrani AS, Carson KA, Shong YK, Kim TY, Viola D, Elisei R, Bendlová B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 42-50. PMID 25332244 DOI: 10.1200/Jco.2014.56.8253 |
0.345 |
|
| 2015 |
Smith BD, Leary CB, Turner BA, Kaufman MD, Wise SC, Garcia-Rendueles MER, Fagin JA, Flynn DL. Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models Cancer Research. 75: 790-790. DOI: 10.1158/1538-7445.Am2015-790 |
0.35 |
|
| 2014 |
Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. The Journal of Clinical Endocrinology and Metabolism. 99: E1976-87. PMID 25029414 DOI: 10.1210/Jc.2013-3976 |
0.464 |
|
| 2014 |
Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of Surgical Oncology. 110: 375-82. PMID 24961938 DOI: 10.1002/Jso.23656 |
0.33 |
|
| 2014 |
Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer. 21: 371-81. PMID 24610577 DOI: 10.1530/Erc-13-0499 |
0.355 |
|
| 2014 |
Chen X, Makarewicz JM, Knauf JA, Johnson LK, Fagin JA. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition. Oncogene. 33: 5442-9. PMID 24240680 DOI: 10.1038/Onc.2013.489 |
0.393 |
|
| 2014 |
Goodwin AF, Tidyman WE, Jheon AH, Sharir A, Zheng X, Charles C, Fagin JA, McMahon M, Diekwisch TG, Ganss B, Rauen KA, Klein OD. Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Human Molecular Genetics. 23: 682-92. PMID 24057668 DOI: 10.1093/Hmg/Ddt455 |
0.315 |
|
| 2013 |
Ricarte-Filho JC, Li S, Garcia-Rendueles ME, Montero-Conde C, Voza F, Knauf JA, Heguy A, Viale A, Bogdanova T, Thomas GA, Mason CE, Fagin JA. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. The Journal of Clinical Investigation. 123: 4935-44. PMID 24135138 DOI: 10.1172/Jci69766 |
0.435 |
|
| 2013 |
Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. The Journal of Clinical Endocrinology and Metabolism. 98: E1562-6. PMID 23833040 DOI: 10.1210/Jc.2013-2383 |
0.445 |
|
| 2013 |
Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocrine-Related Cancer. 20: 659-67. PMID 23828865 DOI: 10.1530/Erc-13-0085 |
0.467 |
|
| 2013 |
Ghossein RA, Katabi N, Fagin JA. Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression. The Journal of Clinical Endocrinology and Metabolism. 98: E1414-21. PMID 23775351 DOI: 10.1210/Jc.2013-1408 |
0.407 |
|
| 2013 |
Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Jama. 309: 1493-501. PMID 23571588 DOI: 10.1001/Jama.2013.3190 |
0.336 |
|
| 2013 |
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, Socci N, Kannan K, Mo Q, Fagin JA, Chan TA. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy. The Journal of Clinical Endocrinology and Metabolism. 98: E962-72. PMID 23543667 DOI: 10.1210/Jc.2012-3539 |
0.421 |
|
| 2013 |
Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. The Journal of Clinical Endocrinology and Metabolism. 98: E829-36. PMID 23533233 DOI: 10.1210/Jc.2012-3933 |
0.425 |
|
| 2013 |
Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, ... ... Fagin JA, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. The New England Journal of Medicine. 368: 623-32. PMID 23406027 DOI: 10.1056/Nejmoa1209288 |
0.408 |
|
| 2013 |
Ryder M, Gild M, Hohl TM, Pamer E, Knauf J, Ghossein R, Joyce JA, Fagin JA. Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression. Plos One. 8: e54302. PMID 23372702 DOI: 10.1371/Journal.Pone.0054302 |
0.445 |
|
| 2013 |
Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discovery. 3: 520-33. PMID 23365119 DOI: 10.1158/2159-8290.Cd-12-0531 |
0.426 |
|
| 2013 |
Agrawal N, Jiao Y, Sausen M, Leary R, Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, Westra WH, Wood LD, Hruban RH, Tufano RP, Robinson B, ... ... Fagin JA, et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. The Journal of Clinical Endocrinology and Metabolism. 98: E364-9. PMID 23264394 DOI: 10.1210/Jc.2012-2703 |
0.358 |
|
| 2013 |
Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Lipson BL, Kurz S, Fagin JA, Pfister DG. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. Journal of Clinical Oncology. 31: 6024-6024. DOI: 10.1200/Jco.2013.31.15_Suppl.6024 |
0.406 |
|
| 2013 |
King LA, Knauf J, Ghossein R, Fagin J, Franco AT. Abstract 4291: Hras versus Braf activation determines follicular versus papillary thyroid cancer development. Cancer Research. 73: 4291-4291. DOI: 10.1158/1538-7445.Am2013-4291 |
0.494 |
|
| 2013 |
Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Abstract 3402: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Research. 73: 3402-3402. DOI: 10.1158/1538-7445.Am2013-3402 |
0.471 |
|
| 2012 |
Couto JP, Daly L, Almeida A, Knauf JA, Fagin JA, Sobrinho-Simões M, Lima J, Máximo V, Soares P, Lyden D, Bromberg JF. STAT3 negatively regulates thyroid tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: E2361-70. PMID 22891351 DOI: 10.1073/Pnas.1201232109 |
0.451 |
|
| 2012 |
Ruiz-Llorente S, Carrillo Santa de Pau E, Sastre-Perona A, Montero-Conde C, Gómez-López G, Fagin JA, Valencia A, Pisano DG, Santisteban P. Genome-wide analysis of Pax8 binding provides new insights into thyroid functions. Bmc Genomics. 13: 147. PMID 22531031 DOI: 10.1186/1471-2164-13-147 |
0.358 |
|
| 2012 |
Ricarte-Filho J, Ganly I, Rivera M, Katabi N, Fu W, Shaha A, Tuttle RM, Fagin JA, Ghossein R. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid : Official Journal of the American Thyroid Association. 22: 575-84. PMID 22471242 DOI: 10.1089/Thy.2011.0431 |
0.321 |
|
| 2012 |
Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, Andersen L, de Boer AS, Manova K, Barlas A, Vundavalli S, Nyborg NC, Knudsen LB, Moelck AM, Fagin JA. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 153: 1538-47. PMID 22234463 DOI: 10.1210/En.2011-1864 |
0.349 |
|
| 2012 |
Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 134-41. PMID 22025146 DOI: 10.1200/Jco.2011.35.5040 |
0.378 |
|
| 2012 |
Ricarte-Filho JC, Matsuse M, Lau C, Ryder M, Nishihara E, Ghossein RA, Ladanyi M, Yamashita S, Mitsutake N, Fagin JA. Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. International Journal of Cancer. 130: 2215-7; author reply. PMID 21717456 DOI: 10.1002/Ijc.26267 |
0.386 |
|
| 2012 |
Sherman EJ, Ho AL, Fury MG, Baxi SS, Haque S, Korte SH, Smith-Marrone S, Xiao H, Ghossein RA, Fagin JA, Pfister DG. A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma. Journal of Clinical Oncology. 30: 5514-5514. DOI: 10.1200/Jco.2012.30.15_Suppl.5514 |
0.367 |
|
| 2011 |
Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. The Journal of Clinical Investigation. 121: 4700-11. PMID 22105174 DOI: 10.1172/Jci46382 |
0.494 |
|
| 2011 |
Rondeau G, Fish S, Hann LE, Fagin JA, Tuttle RM. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid : Official Journal of the American Thyroid Association. 21: 845-53. PMID 21809914 DOI: 10.1089/Thy.2011.0011 |
0.4 |
|
| 2011 |
Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. The Journal of Clinical Endocrinology and Metabolism. 96: 2105-11. PMID 21565788 DOI: 10.1210/Jc.2011-0305 |
0.368 |
|
| 2011 |
Knauf JA, Sartor MA, Medvedovic M, Lundsmith E, Ryder M, Salzano M, Nikiforov YE, Giordano TJ, Ghossein RA, Fagin JA. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene. 30: 3153-62. PMID 21383698 DOI: 10.1038/Onc.2011.44 |
0.367 |
|
| 2011 |
Franco AT, Malaguarnera R, Refetoff S, Liao XH, Lundsmith E, Kimura S, Pritchard C, Marais R, Davies TF, Weinstein LS, Chen M, Rosen N, Ghossein R, Knauf JA, Fagin JA. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice Proceedings of the National Academy of Sciences of the United States of America. 108: 1615-1620. PMID 21220306 DOI: 10.1073/Pnas.1015557108 |
0.472 |
|
| 2011 |
Vitagliano D, De Falco V, Tamburrino A, Coluzzi S, Troncone G, Chiappetta G, Ciardiello F, Tortora G, Fagin JA, Ryan AJ, Carlomagno F, Santoro M. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocrine-Related Cancer. 18: 1-11. PMID 20943719 DOI: 10.1677/Erc-09-0292 |
0.399 |
|
| 2011 |
Chen X, Johnson LK, Knauf JA, Fagin JA. Abstract 4290: The farnesyl transferase inhibitor SCH 66336 induces regression of Hras-driven tumors in mice with widespread endogenous expression of HrasG12V Cancer Research. 71: 4290-4290. DOI: 10.1158/1538-7445.Am2011-4290 |
0.394 |
|
| 2011 |
Silva J, Soares P, Knauf J, Fagin J, Sobrinho-Simoes M, Ghossein R, Bromberg JF. Abstract 1075: STAT3 signaling in thyroid cancer Cancer Research. 71: 1075-1075. DOI: 10.1158/1538-7445.Am2011-1075 |
0.444 |
|
| 2010 |
Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid : Official Journal of the American Thyroid Association. 20: 1341-9. PMID 21034228 DOI: 10.1089/Thy.2010.0178 |
0.334 |
|
| 2010 |
Rivera M, Ricarte-Filho J, Tuttle RM, Ganly I, Shaha A, Knauf J, Fagin J, Ghossein R. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid : Official Journal of the American Thyroid Association. 20: 1085-93. PMID 20860430 DOI: 10.1089/Thy.2010.0174 |
0.347 |
|
| 2010 |
Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Research. 70: 5901-11. PMID 20570890 DOI: 10.1158/0008-5472.Can-10-0192 |
0.371 |
|
| 2010 |
Rivera M, Ricarte-Filho J, Knauf J, Shaha A, Tuttle M, Fagin JA, Ghossein RA. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 23: 1191-200. PMID 20526288 DOI: 10.1038/Modpathol.2010.112 |
0.406 |
|
| 2010 |
Fagin JA, Tuttle RM, Pfister DG. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 95: 2621-4. PMID 20525911 DOI: 10.1210/Jc.2010-0800 |
0.41 |
|
| 2010 |
Rivera M, Ricarte-Filho J, Patel S, Tuttle M, Shaha A, Shah JP, Fagin JA, Ghossein RA. Encapsulated thyroid tumors of follicular cell origin with high grade features (high mitotic rate/tumor necrosis): a clinicopathologic and molecular study. Human Pathology. 41: 172-80. PMID 19913280 DOI: 10.1016/J.Humpath.2009.08.011 |
0.368 |
|
| 2010 |
Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Vasselli JR, Read J, Schlumberger M. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). Journal of Clinical Oncology. 28: 5503-5503. DOI: 10.1200/Jco.2010.28.15_Suppl.5503 |
0.32 |
|
| 2010 |
Silva J, Soares P, Trovisco V, Knauf J, Fagin J, Bromberg J. Abstract 3138: Stat3 signaling in thyroid cancer Cancer Research. 70: 3138-3138. DOI: 10.1158/1538-7445.Am10-3138 |
0.424 |
|
| 2009 |
Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Research. 69: 4885-93. PMID 19487299 DOI: 10.1158/0008-5472.Can-09-0727 |
0.411 |
|
| 2009 |
Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liau L, Cloughesy TC, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America. 106: 9435-40. PMID 19478061 DOI: 10.1073/Pnas.0900571106 |
0.409 |
|
| 2009 |
Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, Wendel HG, Franco A, Knauf JA, Fagin JA. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proceedings of the National Academy of Sciences of the United States of America. 106: 7979-84. PMID 19416908 DOI: 10.1073/Pnas.0900343106 |
0.353 |
|
| 2009 |
Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. The Journal of Clinical Endocrinology and Metabolism. 94: 2092-8. PMID 19318445 DOI: 10.1210/Jc.2009-0247 |
0.378 |
|
| 2009 |
Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Current Opinion in Cell Biology. 21: 296-303. PMID 19231149 DOI: 10.1016/J.Ceb.2009.01.013 |
0.456 |
|
| 2008 |
Fagin JA, Mitsiades N. Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Practice & Research. Clinical Endocrinology & Metabolism. 22: 955-69. PMID 19041825 DOI: 10.1016/J.Beem.2008.09.017 |
0.388 |
|
| 2008 |
Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocrine-Related Cancer. 15: 1069-74. PMID 18719091 DOI: 10.1677/Erc-08-0036 |
0.392 |
|
| 2008 |
Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. The Journal of Clinical Endocrinology and Metabolism. 93: 4331-41. PMID 18713817 DOI: 10.1210/Jc.2008-1102 |
0.342 |
|
| 2008 |
Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4701-4. PMID 18541893 DOI: 10.1200/Jco.2008.17.3682 |
0.408 |
|
| 2008 |
Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Research. 68: 4183-91. PMID 18519677 DOI: 10.1158/0008-5472.Can-08-0413 |
0.381 |
|
| 2008 |
Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. The Journal of Clinical Endocrinology and Metabolism. 93: 2194-201. PMID 18381570 DOI: 10.1210/Jc.2007-2825 |
0.432 |
|
| 2007 |
Fagin JA, Ward LS, Kimura ET. Thyroid cancer: Past, present and future Arquivos Brasileiros De Endocrinologia E Metabologia. 51: 641-642. PMID 17891227 DOI: 10.1590/S0004-27302007000500001 |
0.399 |
|
| 2007 |
Simmons JG, Ling Y, Wilkins H, Fuller CR, D'Ercole AJ, Fagin J, Lund PK. Cell-specific effects of insulin receptor substrate-1 deficiency on normal and IGF-I-mediated colon growth. American Journal of Physiology. Gastrointestinal and Liver Physiology. 293: G995-1003. PMID 17823215 DOI: 10.1152/Ajpgi.00537.2006 |
0.33 |
|
| 2007 |
Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Research. 67: 6956-64. PMID 17638907 DOI: 10.1158/0008-5472.Can-06-4605 |
0.465 |
|
| 2007 |
Ryder M, Nikiforov YE, Fagin JA. Follicular variant papillary thyroid carcinoma arising within an ovarian teratoma. Thyroid : Official Journal of the American Thyroid Association. 17: 179-80. PMID 17316122 DOI: 10.1089/Thy.2006.0093 |
0.425 |
|
| 2006 |
Groussin L, Fagin JA. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nature Clinical Practice. Endocrinology & Metabolism. 2: 180-1. PMID 16932278 DOI: 10.1038/Ncpendmet0161 |
0.406 |
|
| 2006 |
Mesa C, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF, Fagin JA. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research. 66: 6521-9. PMID 16818623 DOI: 10.1158/0008-5472.Can-06-0739 |
0.418 |
|
| 2006 |
Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1785-93. PMID 16551863 DOI: 10.1158/1078-0432.Ccr-05-1729 |
0.46 |
|
| 2006 |
Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. The Journal of Biological Chemistry. 281: 3800-9. PMID 16316983 DOI: 10.1074/Jbc.M511690200 |
0.314 |
|
| 2006 |
Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology. 147: 1014-9. PMID 16254036 DOI: 10.1210/En.2005-0280 |
0.45 |
|
| 2006 |
Steward DL, Tuttle RM, Sofferman RA, Fagin JA. Emerging Trends in Differentiated Thyroid Cancer Management Otolaryngology-Head and Neck Surgery. 135. DOI: 10.1016/J.Otohns.2006.06.380 |
0.363 |
|
| 2005 |
Fagin JA. Genetics of papillary thyroid cancer initiation: implications for therapy. Transactions of the American Clinical and Climatological Association. 116: 259-69; discussion 2. PMID 16555619 |
0.338 |
|
| 2005 |
Puxeddu E, Knauf JA, Sartor MA, Mitsutake N, Smith EP, Medvedovic M, Tomlinson CR, Moretti S, Fagin JA. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocrine-Related Cancer. 12: 319-34. PMID 15947106 DOI: 10.1677/Erc.1.00947 |
0.357 |
|
| 2005 |
Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research. 65: 4238-45. PMID 15899815 DOI: 10.1158/0008-5472.Can-05-0047 |
0.459 |
|
| 2005 |
Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Zhang L, Fagin JA. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Research. 65: 2465-73. PMID 15781663 DOI: 10.1158/0008-5472.Can-04-3314 |
0.441 |
|
| 2005 |
Ciampi R, Knauf JA, Rabes HM, Fagin JA, Nikiforov YE. BRAF kinase activation via chromosomal rearrangement in radiation-induced and sporadic thyroid cancer. Cell Cycle (Georgetown, Tex.). 4: 547-8. PMID 15753649 DOI: 10.4161/Cc.4.4.1631 |
0.398 |
|
| 2005 |
Puxeddu E, Zhao G, Stringer JR, Medvedovic M, Moretti S, Fagin JA. Characterization of novel non-clonal intrachromosomal rearrangements between the H4 and PTEN genes (H4/PTEN) in human thyroid cell lines and papillary thyroid cancer specimens. Mutation Research. 570: 17-32. PMID 15680400 DOI: 10.1016/J.Mrfmmm.2004.09.010 |
0.723 |
|
| 2005 |
Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. The Journal of Clinical Investigation. 115: 94-101. PMID 15630448 DOI: 10.1172/Jci23237 |
0.432 |
|
| 2005 |
Sherman S, Fagin J. Why Thyroid Cancer Thyroid. 15: 303-304. DOI: 10.1089/Thy.2005.15.303 |
0.403 |
|
| 2004 |
Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal of Endocrinology. 183: 249-256. PMID 15531713 DOI: 10.1677/Joe.1.05895 |
0.421 |
|
| 2004 |
Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma Journal of Clinical Endocrinology and Metabolism. 89: 5175-5180. PMID 15472223 DOI: 10.1210/Jc.2003-032221 |
0.376 |
|
| 2004 |
Fagin JA. Challenging dogma in thyroid cancer molecular genetics--role of RET/PTC and BRAF in tumor initiation. The Journal of Clinical Endocrinology and Metabolism. 89: 4264-6. PMID 15356019 DOI: 10.1210/Jc.2004-1426 |
0.403 |
|
| 2004 |
Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE. Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters. 209: 1-6. PMID 15145515 DOI: 10.1016/J.Canlet.2003.12.004 |
0.403 |
|
| 2004 |
Knott AW, Juno RJ, Jarboe MD, Profitt SA, Erwin CR, Smith EP, Fagin JA, Warner BW. Smooth muscle overexpression of IGF-I induces a novel adaptive response to small bowel resection. American Journal of Physiology. Gastrointestinal and Liver Physiology. 287: G562-70. PMID 15142831 DOI: 10.1152/Ajpgi.00438.2003 |
0.312 |
|
| 2004 |
Kimura ET, Vanvooren V, van Sande J, Nikiforov YE, Fagin JA. Autonomously functioning thyroid nodules are not associated with BRAF mutations. Clinical Endocrinology. 60: 394-6. PMID 15009007 DOI: 10.1111/J.1365-2265.2004.01991.X |
0.374 |
|
| 2003 |
Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE. BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas Journal of Clinical Endocrinology and Metabolism. 88: 5399-5404. PMID 14602780 DOI: 10.1210/Jc.2003-030838 |
0.401 |
|
| 2003 |
Puxeddu E, Mitsutake N, Knauf JA, Moretti S, Kim HW, Seta KA, Brockman D, Myatt L, Millhorn DE, Fagin JA. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. The Journal of Biological Chemistry. 278: 52131-8. PMID 14555660 DOI: 10.1074/Jbc.M306003200 |
0.451 |
|
| 2003 |
Knauf JA, Ouyang B, Croyle M, Kimura E, Fagin JA. Acute expression of RET/PTC induces isozyme-specific activation and subsequent downregulation of PKCepsilon in PCCL3 thyroid cells. Oncogene. 22: 6830-8. PMID 14534528 DOI: 10.1038/Sj.Onc.1206829 |
0.398 |
|
| 2003 |
Knauf JA, Kuroda H, Basu S, Fagin JA. RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 22: 4406-12. PMID 12853977 DOI: 10.1038/Sj.Onc.1206602 |
0.417 |
|
| 2003 |
Wang J, Knauf JA, Basu S, Puxeddu E, Kuroda H, Santoro M, Fusco A, Fagin JA. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Molecular Endocrinology (Baltimore, Md.). 17: 1425-36. PMID 12690093 DOI: 10.1210/Me.2003-0041 |
0.454 |
|
| 2003 |
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research. 63: 1454-7. PMID 12670889 |
0.309 |
|
| 2003 |
Castellone MD, Cirafici AM, De Vita G, De Falco V, Malorni L, Tallini G, Fagin JA, Fusco A, Melillo RM, Santoro M. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene. 22: 246-55. PMID 12527893 DOI: 10.1038/Sj.Onc.1206112 |
0.432 |
|
| 2002 |
Williams KL, Fuller CR, Fagin J, Lund PK. Mesenchymal IGF-I overexpression: paracrine effects in the intestine, distinct from endocrine actions. American Journal of Physiology. Gastrointestinal and Liver Physiology. 283: G875-85. PMID 12223347 DOI: 10.1152/Ajpgi.00089.2002 |
0.324 |
|
| 2002 |
Fagin JA. Perspective: lessons learned from molecular genetic studies of thyroid cancer--insights into pathogenesis and tumor-specific therapeutic targets. Endocrinology. 143: 2025-8. PMID 12021165 DOI: 10.1210/Endo.143.6.8832 |
0.353 |
|
| 2002 |
Knauf JA, Ward LS, Nikiforov YE, Nikiforova M, Puxeddu E, Medvedovic M, Liron T, Mochly-Rosen D, Fagin JA. Isozyme-specific abnormalities of PKC in thyroid cancer: Evidence for post-transcriptional changes in PKC epsilon Journal of Clinical Endocrinology and Metabolism. 87: 2150-2159. PMID 11994357 DOI: 10.1210/Jcem.87.5.8441 |
0.459 |
|
| 2002 |
Fagin JA. Minireview: branded from the start-distinct oncogenic initiating events may determine tumor fate in the thyroid. Molecular Endocrinology (Baltimore, Md.). 16: 903-11. PMID 11981026 DOI: 10.1210/Mend.16.5.0838 |
0.379 |
|
| 2002 |
Ouyang B, Knauf JA, Ain K, Nacev B, Fagin JA. Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clinical Endocrinology. 56: 341-50. PMID 11940046 DOI: 10.1046/J.1365-2265.2002.01475.X |
0.443 |
|
| 2002 |
Zhang M, Smith EP, Kuroda H, Banach W, Chernausek SD, Fagin JA. Targeted expression of a protease-resistant IGFBP-4 mutant in smooth muscle of transgenic mice results in IGFBP-4 stabilization and smooth muscle hypotrophy. The Journal of Biological Chemistry. 277: 21285-90. PMID 11923290 DOI: 10.1074/Jbc.M112082200 |
0.322 |
|
| 2001 |
Zhu B, Zhao G, Witte DP, Hui DY, Fagin JA. Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology. 142: 3598-606. PMID 11459808 DOI: 10.1210/Endo.142.8.8331 |
0.695 |
|
| 2001 |
Puxeddu E, Fagin JA. Genetic markers in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America. 30: 493-513. PMID 11444172 DOI: 10.1016/S0889-8529(05)70196-1 |
0.413 |
|
| 2001 |
Mochly-Rosen D, Fagin JA, Knauf JA, Nikiforov Y, Liron T, Schechtman D. Spontaneous occurrence of an inhibitor of protein kinase C localization in a thyroid cancer cell line: role in thyroid tumorigenesis. Advances in Enzyme Regulation. 41: 87-97. PMID 11384739 DOI: 10.1016/S0065-2571(00)00008-X |
0.427 |
|
| 2001 |
Zhao G, Sutliff RL, Weber CS, Wang J, Lorenz J, Paul RJ, Fagin JA. Smooth muscle-targeted overexpression of insulin-like growth factor I results in enhanced vascular contractility. Endocrinology. 142: 623-32. PMID 11159833 DOI: 10.1210/Endo.142.2.7941 |
0.695 |
|
| 2000 |
Shirokawa JM, Elisei R, Knauf JA, Hara T, Wang J, Saavedra HI, Fagin JA. Conditional apoptosis induced by oncogenic ras in thyroid cells. Molecular Endocrinology. 14: 1725-1738. PMID 11075808 DOI: 10.1210/Mend.14.11.0559 |
0.358 |
|
| 2000 |
Martelli ML, Miano MG, Battaglia C, Trapasso F, Stella A, Iuliano R, Visconti R, Fagin JA, Santoro M, Fusco A. The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive European Journal of Endocrinology. 143: 515-521. PMID 11022199 DOI: 10.1530/Eje.0.1430515 |
0.417 |
|
| 2000 |
Nikiforova MN, Stringer JR, Blough R, Medvedovic M, Fagin JA, Nikiforov YE. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science (New York, N.Y.). 290: 138-41. PMID 11021799 DOI: 10.1126/Science.290.5489.138 |
0.349 |
|
| 2000 |
Saavedra HI, Knauf JA, Shirokawa JM, Wang J, Ouyang B, Elisei R, Stambrook PJ, Fagin JA. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway Oncogene. 19: 3948-3954. PMID 10951588 DOI: 10.1038/Sj.Onc.1203723 |
0.331 |
|
| 2000 |
Stuart WD, Maeda S, Khera P, Fagin JA, Clemens TL. Parathyroid hormone-related protein induces G1 phase growth arrest of vascular smooth muscle cells. American Journal of Physiology-Endocrinology and Metabolism. 279. PMID 10893323 DOI: 10.1152/Ajpendo.2000.279.1.E60 |
0.304 |
|
| 2000 |
Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 141: 2674-82. PMID 10875273 DOI: 10.1210/Endo.141.7.7585 |
0.681 |
|
| 1999 |
Nikiforov YE, Koshoffer A, Nikiforova M, Stringer J, Fagin JA. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene. 18: 6330-4. PMID 10597232 DOI: 10.1038/Sj.Onc.1203019 |
0.319 |
|
| 1999 |
Knauf JA, Elisei R, Mochly-Rosen D, Liron T, Chen XN, Gonsky R, Korenberg JR, Fagin JA. Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. The Journal of Biological Chemistry. 274: 23414-25. PMID 10438519 DOI: 10.1074/Jbc.274.33.23414 |
0.423 |
|
| 1999 |
Maeda S, Sutliff RL, Qian J, Lorenz JN, Wang J, Tang H, Nakayama T, Weber C, Witte D, Strauch AR, Paul RJ, Fagin JA, Clemens TL. Targeted overexpression of parathyroid hormone-related protein (PTHrP) to vascular smooth muscle in transgenic mice lowers blood pressure and alters vascular contractility. Endocrinology. 140: 1815-25. PMID 10098520 DOI: 10.1210/Endo.140.4.6646 |
0.3 |
|
| 1998 |
Elisei R, Shiohara M, Koeffler HP, Fagin JA. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer. 83: 2185-93. PMID 9827724 DOI: 10.1002/(Sici)1097-0142(19981115)83:10<2185::Aid-Cncr18>3.0.Co;2-4 |
0.385 |
|
| 1998 |
Nikiforov YE, Nikiforova M, Fagin JA. Prevalence of minisatellite and microsatellite instability in radiation-induced post-Chernobyl pediatric thyroid carcinomas. Oncogene. 17: 1983-8. PMID 9788442 DOI: 10.1038/Sj.Onc.1202120 |
0.398 |
|
| 1998 |
Chen X, Knauf JA, Gonsky R, Wang M, Lai EH, Chissoe S, Fagin JA, Korenberg JR. From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. American Journal of Human Genetics. 63: 625-37. PMID 9683604 DOI: 10.1086/301973 |
0.317 |
|
| 1998 |
Motomura T, Nikiforov YE, Namba H, Ashizawa K, Nagataki S, Yamashita S, Fagin JA. ret rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid : Official Journal of the American Thyroid Association. 8: 485-9. PMID 9669285 DOI: 10.1089/Thy.1998.8.485 |
0.358 |
|
| 1998 |
Wang J, Niu W, Witte DP, Chernausek SD, Nikiforov YE, Clemens TL, Sharifi B, Strauch AR, Fagin JA. Overexpression of insulin-like growth factor-binding protein-4 (IGFBP-4) in smooth muscle cells of transgenic mice through a smooth muscle alpha-actin-IGFBP-4 fusion gene induces smooth muscle hypoplasia. Endocrinology. 139: 2605-14. PMID 9564877 DOI: 10.1210/Endo.139.5.5986 |
0.347 |
|
| 1998 |
Ward LS, Brenta G, Medvedovic M, Fagin JA. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas Journal of Clinical Endocrinology and Metabolism. 83: 525-530. PMID 9467569 DOI: 10.1210/Jcem.83.2.4550 |
0.401 |
|
| 1997 |
Nikiforov YE, Fagin JA. Risk factors for thyroid cancer. Trends in Endocrinology and Metabolism. 8: 20-25. PMID 18406782 DOI: 10.1016/S1043-2760(96)00204-4 |
0.376 |
|
| 1997 |
Gonsky R, Knauf JA, Elisei R, Wang JW, Su S, Fagin JA. Identification of Rapid Turnover Transcripts Overexpressed in Thyroid Tumors and Thyroid Cancer Cell Lines: Use of a Targeted Differential RNA Display Method to Select for mRNA Subsets Nucleic Acids Research. 25: 3823-3831. PMID 9380504 DOI: 10.1093/Nar/25.19.3823 |
0.413 |
|
| 1997 |
Wang J, Niu W, Nikiforov Y, Naito S, Chernausek S, Witte D, LeRoith D, Strauch A, Fagin JA. Targeted overexpression of IGF-I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. The Journal of Clinical Investigation. 100: 1425-39. PMID 9294108 DOI: 10.1172/Jci119663 |
0.353 |
|
| 1997 |
Nikiforov YE, Fagin JA. Prevalence, Significance, and Biological Behavior of ret/PTC Associated Papillary Thyroid Carcinoma— Author’s Response 1 The Journal of Clinical Endocrinology and Metabolism. 82: 2016-2017. DOI: 10.1210/Jcem.82.6.9996 |
0.332 |
|
| 1996 |
Spambalg D, Sharifi N, Elisei R, Gross JL, Medeiros-Neto G, Fagin JA. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. The Journal of Clinical Endocrinology and Metabolism. 81: 3898-3901. PMID 8923835 DOI: 10.1210/Jcem.81.11.8923835 |
0.425 |
|
| 1996 |
Nikiforov Y, Gnepp DR, Fagin JA. Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. The Journal of Clinical Endocrinology and Metabolism. 81: 9-14. PMID 8550800 DOI: 10.1210/Jcem.81.1.8550800 |
0.326 |
|
| 1995 |
Okano K, Pirola CJ, Wang HM, Forrester JS, Fagin JA, Clemens TL. Involvement of cell cycle and mitogen-activated pathways in induction of parathyroid hormone-related protein gene expression in rat aortic smooth muscle cells Endocrinology. 136: 1782-1789. PMID 7895691 DOI: 10.1210/Endo.136.4.7895691 |
0.346 |
|
| 1995 |
Herman-Bonert V, Fagin JA. Molecular pathogenesis of pituitary tumours. BaillièRe's Clinical Endocrinology and Metabolism. 9: 203-223. PMID 7625983 DOI: 10.1016/S0950-351X(95)80290-8 |
0.345 |
|
| 1995 |
Chen X, Gonsky R, Wang M, Lai E, Fagin J, Korenberg J. Gene amplification in thyroid cancer: A new mechanism defined by CGH and A BAC map of the human genome Cancer Genetics and Cytogenetics. 84: 134. DOI: 10.1016/0165-4608(96)85229-0 |
0.343 |
|
| 1994 |
Okano K, Wu S, Huang X, Pirola CJ, Juppner H, Abou-Samra AB, Segre GV, Iwasaki K, Fagin JA, Clemens TL. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor and its messenger ribonucleic acid in rat aortic vascular smooth muscle cells and UMR osteoblast-like cells: cell-specific regulation by angiotensin-II and PTHrP. Endocrinology. 135: 1093-1099. PMID 8070351 DOI: 10.1210/Endo.135.3.8070351 |
0.319 |
|
| 1994 |
Zeki K, Spambalg D, Sharifi N, Gonsky R, Fagin JA. Mutations of the adenomatous polyposis coli gene in sporadic thyroid neoplasms. The Journal of Clinical Endocrinology and Metabolism. 79: 1317-1321. PMID 7962323 DOI: 10.1210/Jcem.79.5.7962323 |
0.433 |
|
| 1994 |
Kamyar A, Pirola CJ, Wang HM, Sharifi B, Mohan S, Forrester JS, Fagin JA. Expression and insulin-like growth factor-dependent proteolysis of insulin-like growth factor-binding protein-4 are regulated by cell confluence in vascular smooth muscle cells Circulation Research. 74: 576-585. PMID 7511071 DOI: 10.1161/01.Res.74.4.576 |
0.328 |
|
| 1993 |
Matsuo K, Friedman E, Gejman PV, Fagin JA. The thyrotropin receptor (TSH-R) is not an oncogene for thyroid tumors: structural studies of the TSH-R and the alpha-subunit of Gs in human thyroid neoplasms. The Journal of Clinical Endocrinology and Metabolism. 76: 1446-51. PMID 8501149 DOI: 10.1210/Jcem.76.6.8501149 |
0.398 |
|
| 1993 |
Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH, Koeffler HP. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. The Journal of Clinical Investigation. 91: 179-84. PMID 8423216 DOI: 10.1172/Jci116168 |
0.451 |
|
| 1993 |
Matsuo K, Tang SH, Sharifi B, Rubin SA, Schreck R, Fagin JA. Growth factor production by human thyroid carcinoma cells: Abundant expression of a platelet-derived growth factor-B-like protein by a human papillary carcinoma cell line Journal of Clinical Endocrinology and Metabolism. 77: 996-1004. PMID 8408476 DOI: 10.1210/Jcem.77.4.8408476 |
0.379 |
|
| 1993 |
Matsuo K, Tang S, Zeki K, Gutman RA, Fagin JA. Aberrant deoxyribonucleic acid methylation in human thyroid tumors The Journal of Clinical Endocrinology and Metabolism. 77: 991-995. PMID 7691865 DOI: 10.1210/Jcem.77.4.7691865 |
0.324 |
|
| 1992 |
Khorsandi M, Fagin JA, Fishbein MC, Forrester JS, Cercek B. Effects of hypophysectomy on vascular insulin-like growth factor-I gene expression after balloon denudation in rats Atherosclerosis. 93: 115-122. PMID 1596294 DOI: 10.1016/0021-9150(92)90205-U |
0.327 |
|
| 1992 |
Fagin JA. Genetic basis of endocrine disease 3: Molecular defects in thyroid gland neoplasia. The Journal of Clinical Endocrinology and Metabolism. 75: 1398-1400. PMID 1464638 DOI: 10.1210/Jcem.75.6.1464638 |
0.321 |
|
| 1992 |
Khorsandi MJ, Fagin JA, Giannella-Neto D, Forrester JS, Cercek B. Regulation of insulin-like growth factor-I and its receptor in rat aorta after balloon denudation: Evidence for local bioactivity Journal of Clinical Investigation. 90: 1926-1931. PMID 1430215 DOI: 10.1172/Jci116070 |
0.32 |
|
| 1992 |
Giannella-Neto D, Kamyar A, Sharifi B, Pirola CJ, Kupfer J, Rosenfeld RG, Forrester JS, Fagin JA. Platelet-derived growth factor isoforms decrease insulin-like growth factor I gene expression in rat vascular smooth muscle cells and selectively stimulate the biosynthesis of insulin-like growth factor binding protein 4 Circulation Research. 71: 646-656. PMID 1379893 DOI: 10.1161/01.Res.71.3.646 |
0.342 |
|
| 1991 |
Namba H, Ross JL, Goodman D, Fagin JA. Solitary polyclonal autonomous thyroid nodule: a rare cause of childhood hyperthyroidism. The Journal of Clinical Endocrinology and Metabolism. 72: 1108-12. PMID 2022710 DOI: 10.1210/Jcem-72-5-1108 |
0.406 |
|
| 1991 |
Matsuo K, Tang S, Fagin JA. Allelotype of human thyroid tumors: loss of chromosome 11q13 sequences in follicular neoplasms. Molecular Endocrinology. 5: 1873-1879. PMID 1791835 DOI: 10.1210/Mend-5-12-1873 |
0.319 |
|
| 1990 |
Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis Molecular Endocrinology. 4: 1474-1479. PMID 2283998 DOI: 10.1210/Mend-4-10-1474 |
0.369 |
|
| 1990 |
Namba H, Gutman RA, Matsuo K, Alvarez A, Fagin JA. H-ras protooncogene mutations in human thyroid neoplasms. The Journal of Clinical Endocrinology and Metabolism. 71: 223-229. PMID 2196280 DOI: 10.1210/Jcem-71-1-223 |
0.328 |
|
| 1990 |
Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation Circulation Research. 66: 1755-1760. PMID 2188750 DOI: 10.1161/01.Res.66.6.1755 |
0.34 |
|
| 1990 |
Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal Origin of Pituitary Adenomas The Journal of Clinical Endocrinology and Metabolism. 71: 1427-1433. PMID 1977759 DOI: 10.1210/Jcem-71-6-1427 |
0.309 |
|
| 1990 |
Namba H, Matsuo K, Fagin JA. Clonal composition of benign and malignant human thyroid tumors. Journal of Clinical Investigation. 86: 120-125. PMID 1973172 DOI: 10.1172/Jci114673 |
0.423 |
|
| 1989 |
Fagin JA, Fernandez-Mejia C, Melmed S. Pituitary Insulin-Like Growth Factor-I Gene Expression: Regulation by Triiodothyronine and Growth Hormone Endocrinology. 125: 2385-2391. PMID 2791994 DOI: 10.1210/Endo-125-5-2385 |
0.352 |
|
| 1988 |
Fagin JA, Brown A, Melmed S. Regulation of pituitary insulin-like growth factor-I messenger ribonucleic acid levels in rats harboring somatomammotropic tumors: implications for growth hormone autoregulation. Endocrinology. 122: 2204-2210. PMID 3359980 DOI: 10.1210/Endo-122-5-2204 |
0.336 |
|
| 1987 |
Fagin JA, Pixley S, Slanina S, Ong J, Melmed S. Insulin-like growth factor I gene expression in GH3 rat pituitary cells: Messenger ribonucleic acid content, immunocytochemistry, and secretion Endocrinology. 120: 2037-2043. PMID 3552629 DOI: 10.1210/Endo-120-5-2037 |
0.362 |
|
| 1986 |
Yamashita S, Ong J, Fagin JA, Melmed S. Expression of the myc cellular proto-oncogene in human thyroid tissue. The Journal of Clinical Endocrinology and Metabolism. 63: 1170-1173. PMID 3760117 DOI: 10.1210/Jcem-63-5-1170 |
0.393 |
|
| 1986 |
Melmed S, Fagin J, Leung M. Bromocriptine inhibits incorporation of [3H]thymidine into rat pituitary tumor cells Brain Research. 369: 83-90. PMID 3697756 DOI: 10.1016/0006-8993(86)90515-9 |
0.319 |
|
| 1986 |
Melmed S, Fagin JA. Isolation and characterization of rat-mouse somatic cell hybrids secreting growth hormone and prolactin. Experimental Cell Research. 162: 475-485. PMID 3510881 DOI: 10.1016/0014-4827(86)90351-4 |
0.322 |
|
| Show low-probability matches. |